Real‐world resource use and costs of adjuvant treatment for stage III colon cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2354|24|3|321-332

ISSN： 0961-5423

Source： EUROPEAN JOURNAL OF CANCER CARE (ELECTRONIC), Vol.24, Iss.3, 2015-05, pp. : 321-332

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

By Punt C.J.   Nagy A.   Douillard J.-Y.   Figer A.   Skovsgaard T.   Monson J.   Barone C.   Fountzilas G.   Riess H.   Moylan E.   Jones D.   Dethling J.   Colman J.   Coward L.   MacGregor S.  

The Lancet, Vol. 360, Iss. 334, 2002-08 ,pp. : 671-677

Elsevier

Access to resources Recommend Favorite

Economic Impact of Alternative Adjuvant Chemotherapy Regimens for Stage III Colon Cancer

By  

Oncology Research and Treatment, Vol. 32, Iss. 11, 2009-10 ,pp. : 647-652

Karger

Access to resources Recommend Favorite

Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting

By  

Oncology, Vol. 72, Iss. 3-4, 2008-01 ,pp. : 248-254

Karger

Access to resources Recommend Favorite

Adjuvant Chemotherapy in Stage III Colon Cancer with 5-Fluorouracil and Levamisole versus 5-Fluorouracil and Leucovorin

By  

Oncology Research and Treatment, Vol. 25, Iss. 5, 2002-11 ,pp. : 426-430

Karger

Access to resources Recommend Favorite

Adjuvant Therapy with Edrecolomab versus Observation in Stage II Colon Cancer: A Multicenter Randomized Phase III Study*

By  

Oncology Research and Treatment, Vol. 28, Iss. 6-7, 2005-06 ,pp. : 347-350

Karger

Access to resources Recommend Favorite